ATE232722T1 - Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung - Google Patents
Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzungInfo
- Publication number
- ATE232722T1 ATE232722T1 AT96909319T AT96909319T ATE232722T1 AT E232722 T1 ATE232722 T1 AT E232722T1 AT 96909319 T AT96909319 T AT 96909319T AT 96909319 T AT96909319 T AT 96909319T AT E232722 T1 ATE232722 T1 AT E232722T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclosporin
- lactide
- poly
- nanospheres
- formulation
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 6
- 229930105110 Cyclosporin A Natural products 0.000 title abstract 6
- 108010036949 Cyclosporine Proteins 0.000 title abstract 6
- 229960001265 ciclosporin Drugs 0.000 title abstract 6
- 229930182912 cyclosporin Natural products 0.000 title abstract 6
- 239000002077 nanosphere Substances 0.000 title abstract 5
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 5
- 239000004005 microsphere Substances 0.000 abstract 4
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 abstract 3
- 229920002988 biodegradable polymer Polymers 0.000 abstract 3
- 239000004621 biodegradable polymer Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000747 poly(lactic acid) Polymers 0.000 abstract 1
- 229940065514 poly(lactide) Drugs 0.000 abstract 1
- -1 poly(lactide) Polymers 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/795—Composed of biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/931—Medical device coating
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE950233A IE75744B1 (en) | 1995-04-03 | 1995-04-03 | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
PCT/IE1996/000017 WO1996031202A1 (en) | 1995-04-03 | 1996-04-02 | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE232722T1 true ATE232722T1 (de) | 2003-03-15 |
Family
ID=11040700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96909319T ATE232722T1 (de) | 1995-04-03 | 1996-04-02 | Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung |
Country Status (14)
Country | Link |
---|---|
US (1) | US5641745A (de) |
EP (1) | EP0818996B1 (de) |
JP (1) | JP3875721B2 (de) |
AT (1) | ATE232722T1 (de) |
AU (1) | AU700612B2 (de) |
CA (1) | CA2217462C (de) |
DE (1) | DE69626278T2 (de) |
DK (1) | DK0818996T3 (de) |
ES (1) | ES2189868T3 (de) |
IE (1) | IE75744B1 (de) |
NZ (1) | NZ304975A (de) |
PT (1) | PT818996E (de) |
WO (1) | WO1996031202A1 (de) |
ZA (1) | ZA962670B (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
EP1010435B1 (de) * | 1997-09-05 | 2010-11-03 | Maruho K.K. | Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen |
NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
PL192273B1 (pl) * | 1997-09-25 | 2006-09-29 | Bayer Ag | Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej |
US6657104B1 (en) | 1997-10-16 | 2003-12-02 | Texas Systems, University Of The Board Of The Regents | Transgenic mouse model for cardiac hypertrophy and methods of use thereof |
DE19821951A1 (de) * | 1998-05-15 | 1999-11-18 | Basf Ag | Cyclosporin-Zubereitungen |
US20040259895A1 (en) * | 1998-05-28 | 2004-12-23 | Medical Research Institute | Oral formulation of lipid soluble thiamine and lipoic acid |
US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
US20050085498A1 (en) * | 1998-05-28 | 2005-04-21 | Byrd Edward A. | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate |
US6905707B2 (en) * | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
US6984404B1 (en) | 1998-11-18 | 2006-01-10 | University Of Florida Research Foundation, Inc. | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
IL143604A0 (en) | 1998-12-30 | 2002-04-21 | Dexcel Ltd | Dispersable concentrate for the delivery of cyclosporin |
US6253463B1 (en) | 1999-04-26 | 2001-07-03 | Niro A/S | Method of spray drying |
US6406745B1 (en) | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
GB9920558D0 (en) * | 1999-08-31 | 1999-11-03 | Bradford Particle Design Ltd | Methods for particle formation and their products |
GB2381453A (en) * | 1999-08-31 | 2003-05-07 | Bradford Particle Design Ltd | Active/polymer coformulations |
US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
US6682754B2 (en) | 1999-11-24 | 2004-01-27 | Willmar Poultry Company, Inc. | Ovo delivery of an immunogen containing implant |
US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
US6565888B1 (en) * | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US6607784B2 (en) * | 2000-12-22 | 2003-08-19 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
US9700866B2 (en) * | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
AR033711A1 (es) * | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
KR100978836B1 (ko) * | 2001-10-19 | 2010-08-30 | 이소테크니카 인코포레이티드 | 신규한 시클로스포린 유사체 미세유화액 예비농축물 |
DK1714977T3 (da) | 2001-10-19 | 2009-07-06 | Isotechnika Inc | Syntese af cyclosporinanaloger |
KR20030065831A (ko) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | 사이클로스포린을 함유한 지속 방출형 약학적 조성물 |
MXPA04009385A (es) * | 2002-03-26 | 2005-01-25 | Teva Pharma | Microparticulas de drogas. |
EP1576138B1 (de) | 2002-11-15 | 2017-02-01 | Idenix Pharmaceuticals LLC. | 2'-methyl nukleoside in kombination mit interferon und flaviviridae-mutation |
US20040150061A1 (en) * | 2003-01-30 | 2004-08-05 | Hsin Chung Hsien | Package structure of a photosensor |
US7507823B2 (en) | 2004-05-06 | 2009-03-24 | Bristol-Myers Squibb Company | Process of making aripiprazole particles |
GB0413729D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
GB0413730D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
US20080280973A1 (en) * | 2004-06-28 | 2008-11-13 | Wender Paul A | Laulimalide Analogues as Therapeutic Agents |
KR20070100836A (ko) * | 2005-02-03 | 2007-10-11 | 신벤션 아게 | 졸/겔 기술에 의하여 제조된 약물 전달 물질 |
CN1323096C (zh) * | 2005-05-26 | 2007-06-27 | 中国科学院长春应用化学研究所 | 生物可降解聚酯微粒及其制备方法和用途 |
US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
CA2608930A1 (en) * | 2005-06-14 | 2006-12-28 | Baxter International Inc. | Pharmaceutical formulations for minimizing drug-drug interactions |
CA2628630A1 (en) * | 2005-11-15 | 2007-05-24 | Baxter International Inc. | Compositions of lipoxygenase inhibitors |
US20070298067A1 (en) * | 2006-06-22 | 2007-12-27 | Boston Scientific Scimed, Inc. | Control release drug coating for medical devices |
US7794495B2 (en) * | 2006-07-17 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Controlled degradation of stents |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
EP2200613B1 (de) | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazin-derivate und ihre verwendungen |
US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
US20170065533A1 (en) * | 2011-01-24 | 2017-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles for dermal and systemic delivery of drugs |
US10624847B2 (en) * | 2011-08-02 | 2020-04-21 | AnPac BioMedical Science Co., Ltd. | Decomposable apparatus and methods for fabricating same |
EP2785184B1 (de) | 2011-11-30 | 2020-06-10 | Emory University | ZUSAMMENSETZUNGEN ENTHAlTEND JAK-HEMMER UND HAART-MEDIKAMENTE ZUR VORBEUGUNG ODER BEHANDLUNG VON HIV |
US9034347B2 (en) * | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
EP2925314B1 (de) | 2012-11-28 | 2020-04-01 | Aphios Corporation | Kombinationstherapeutika sowie verfahren zur behandlung von neurodegenerativen und anderen erkrankungen |
WO2015138919A1 (en) | 2014-03-14 | 2015-09-17 | The University Of North Carolina At Chapel Hill | Small molecules for inhibiting male fertility |
GB201522441D0 (en) * | 2015-12-18 | 2016-02-03 | Midatech Pharma Wales Ltd | Sustained release cyclosporine-loaded microparticles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1311686C (en) * | 1986-06-25 | 1992-12-22 | John Weldon Shell | Controlled release bioerodible drug delivery system |
DE3851152T2 (de) * | 1987-09-03 | 1995-01-26 | Univ Georgia Res Found | Cyclosporin-augenmittel. |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US5185152A (en) * | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
WO1991016057A1 (en) * | 1990-04-18 | 1991-10-31 | University Of Utah | COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING pH-DEPENDENT SWELLING |
US5171217A (en) * | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
DE69225979T2 (de) * | 1992-08-13 | 1998-12-17 | Teikoku Seiyaku Kk | Orale zubereitung zur freisetzung im unteren verdauungstract |
-
1995
- 1995-04-03 IE IE950233A patent/IE75744B1/en not_active IP Right Cessation
- 1995-06-07 US US08/479,509 patent/US5641745A/en not_active Expired - Lifetime
-
1996
- 1996-04-02 WO PCT/IE1996/000017 patent/WO1996031202A1/en active IP Right Grant
- 1996-04-02 PT PT96909319T patent/PT818996E/pt unknown
- 1996-04-02 AT AT96909319T patent/ATE232722T1/de active
- 1996-04-02 AU AU52866/96A patent/AU700612B2/en not_active Ceased
- 1996-04-02 DK DK96909319T patent/DK0818996T3/da active
- 1996-04-02 NZ NZ304975A patent/NZ304975A/en not_active IP Right Cessation
- 1996-04-02 ES ES96909319T patent/ES2189868T3/es not_active Expired - Lifetime
- 1996-04-02 CA CA2217462A patent/CA2217462C/en not_active Expired - Fee Related
- 1996-04-02 EP EP96909319A patent/EP0818996B1/de not_active Expired - Lifetime
- 1996-04-02 JP JP53015696A patent/JP3875721B2/ja not_active Expired - Fee Related
- 1996-04-02 DE DE69626278T patent/DE69626278T2/de not_active Expired - Lifetime
- 1996-04-03 ZA ZA962670A patent/ZA962670B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2217462A1 (en) | 1996-10-10 |
WO1996031202A1 (en) | 1996-10-10 |
IE950233A1 (en) | 1996-10-16 |
ZA962670B (en) | 1996-10-09 |
EP0818996B1 (de) | 2003-02-19 |
AU5286696A (en) | 1996-10-23 |
PT818996E (pt) | 2003-06-30 |
EP0818996A1 (de) | 1998-01-21 |
DE69626278T2 (de) | 2003-07-24 |
JP3875721B2 (ja) | 2007-01-31 |
JPH11503147A (ja) | 1999-03-23 |
IE75744B1 (en) | 1997-09-24 |
DK0818996T3 (da) | 2003-06-10 |
ES2189868T3 (es) | 2003-07-16 |
CA2217462C (en) | 2010-08-03 |
US5641745A (en) | 1997-06-24 |
DE69626278D1 (de) | 2003-03-27 |
AU700612B2 (en) | 1999-01-07 |
NZ304975A (en) | 1998-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE232722T1 (de) | Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung | |
AU2001255509B2 (en) | Taste masking coating composition | |
BG102438A (en) | Medicamentous form | |
BR9810124A (pt) | Um itraconazol exibindo solibilidade incrementada, o método de preparação do mesmo e a composição farmacêutica para administração oral contendo o mesmo | |
CY1105908T1 (el) | Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο | |
GEP20032912B (en) | Enteric Coated Pharmaceutical Tablets and Method of Manufacturing | |
WO1997013502A3 (en) | Prolonged release of gm-csf | |
WO1998009597A3 (en) | Cushioning beads and tablet comprising the same capable of forming a suspension | |
IL111647A (en) | Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation | |
EP1120109A3 (de) | Feste schnell zerfallende und sich auflösende Dosierungsformen | |
CA2285266A1 (en) | Extended release formulations of erythromycin derivatives | |
HUP0203451A2 (hu) | Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra | |
BR0008059A (pt) | Composições de valdecoxib | |
AU5895596A (en) | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids | |
CA2414241A1 (en) | Polymeric micelle compositions | |
PT820300E (pt) | Nanoparticulas biodegradaveis de libertacao controlada contendo insulina | |
CA2315261A1 (en) | Oral pharmaceutical extended release dosage form | |
IL84167A0 (en) | Compositions containing bioactive materials adapted for oral administration and methods for administration thereof | |
Ain et al. | Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug (s) | |
NZ510563A (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
CA2219777A1 (en) | Nanoparticles for oral administration of pharmaceutical agents of low solubility | |
DE60006362D1 (de) | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen | |
Trivedi et al. | Colon targeted delivery system (CODESTM): propitious approach in targeting colon | |
RS20050866A (en) | Controlled release pharmaceutical composition comprising an acid- insoluble and a bioadhesive polymer | |
DE69907479D1 (de) | Piroxicam enthaltende gastrointestinale Zubereitung aus merheren Einheiten bestehend |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0818996 Country of ref document: EP |
|
EEIH | Change in the person of patent owner |